Novel targets for the treatment of obesity: A review of progress

Drug Discovery Today: Therapeutic Strategies

Volumn 1, Issue 2, 2004, Pages 227-235

  Cheetham, Sharon C ^a   Jackson, Helen C ^a   Vickers, Steven P ^a   Dickinson, Keith ^a   Jones, Robert B ^a   Heal, David J ^a  

^a RenaSci Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,4 BENZODIOXAN 2 CARBOXYLIC ACID; A 331440; AMFEBUTAMONE; ANTIOBESITY AGENT; AOD 9604; ATL 962; DOPAMINE; FENFLURAMINE; GI 181771; MELANIN CONCENTRATING HORMONE; MONOAMINE; NEUROPEPTIDE; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NORADRENALIN; P 57; PHENTERMINE; PLACEBO; RECOMBINANT CILIARY NEUROTROPHIC FACTOR; RIMONABANT; SEROTONIN; SEROTONIN ANTAGONIST; SIBUTRAMINE; SOLABEGRON; SR 146131; SSR 125180; TETRAHYDROLIPSTATIN; TOPIRAMATE; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BODY WEIGHT; BRADYCARDIA; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONFUSION; DIET THERAPY; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EXERCISE; GASTROINTESTINAL SYMPTOM; GENE TARGETING; HUMAN; HYPERTENSION; MITRAL VALVE DISEASE; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PARESTHESIA; REVIEW; RISK FACTOR; SKIN TINGLING; TACHYCARDIA; TREMOR; WEIGHT REDUCTION;

EID: 13344294295     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2004.09.009     Document Type: Review

References (32)

1. 1 receptor antagonist, in diet-induced mice Am. J. Physiol. 284 2003 R345-R353
2. A. Preti Axokine (Regeneron) Drugs 6 2003 696-701
3. J.W. Anderson et al. Bupropion SR enhances weight loss: A 48-week double-blind, placebo-controlled trial Obes. Res. 10 2002 633-641
4. F.M. Ng et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone Horm. Res. 53 2000 274-278
5. M.A. Heffernan et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment Int. J. Obes. Relat. Metab. Disord. 10 2001 1442-1449
6. J.R. Szewczyk C. Laudeman CCK1R agonists: A promising target for the pharmacological treatment of obesity Curr. Top. Med. Chem. 3 2003 837-854
7. H. Masusaki et al. A transgenic model of visceral obesity and the metabolic syndrome Science 294 2001 2166-2170
8. S.P. Vickers C.T. Dourish Serotonin receptor ligands and the treatment of obesity Curr. Opin. Investig. Drugs 5 2004 377-378
9. 2C receptor agonists as potential drugs for the treatment of obesity Curr. Top. Med. Chem. 3 2003 885-897
10. N.R. Levens O. Della-Zuana Neuropeptide Y Y5 receptor antagonists as anti-obesity drugs Curr. Opin. Investig. Drugs 4 2003 1198-1204
11. M.M. Berglund et al. Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes Exp. Biol. Med. 228 2003 217-244
12. R.L. Batterham S.R. Bloom The gut hormone peptide YY regulates appetite Ann. N.Y. Acad. Sci. 994 2003 162-168
13. M.L. Woolley et al. A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze Neuropharmacology 41 2001 210-219
14. W.D. Hirst et al. Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modelling Mol. Pharmacol. 64 2003 1295-1308
15. 3 receptor antagonists/inverse agonists as anti-obesity agents Curr. Opin. Investig. Drugs 4 2003 1190-1197
16. 3 receptors results in changes in brain histamine tone leading to an obese phenotype J. Clin. Invest. 110 2002 1791-1799
17. B. Borowsky et al. Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist Nature Med. 202 2002 825-830
18. C.A. Collins P.R. Kym Prospects for obesity treatment: MCH receptor antagonists Curr. Opin. Investig. Drugs 4 2003 386-394
19. L.P. Shearman et al. Chronic MCH-1 receptor modulation alters appetite, body weight and adiposity in rats Eur. J. Pharmacol. 475 2003 37-47
20. W. Fan et al. The central melanocortin system can directly regulate serum insulin levels Endocrinology 141 2000 3072-3079
21. V.S. Goodfellow J. Saunders The melanocortin system and its role in obesity and cachexia Curr. Top. Med. Chem. 3 2003 855-883
22. S. O'Rahilly et al. Melanocortin receptors weigh-in Nat. Med. 10 2004 351-352
23. M.M. Veniant C.P. LeBel Leptin: From animals to humans Curr. Pharm. Des. 9 2003 811-818
24. J.N. Thupari et al. Chronic C75 treatment of diet-induced obese mice increases fat oxidation and reduces food intake to reduce adipose mass Am. J. Physiol. Endocrinol. Metab. 287 2004 E97-E104
25. T.L. Horvath et al. Ghrelin as a potential anti-obesity target Curr. Pharm. Des. 9 2003 1383-1395
26. K.E. Wortley et al. Deletion of ghrelin reveals no effect on food intake, but a primary role in energy balance Obes. Res. 12 2004 170
27. G.J. Grover et al. Selective thyroid hormone receptor-β activation: a strategy for reduction of weight, cholesterol and lipoprotein (a) with reduced cardiovascular liability Proc. Natl. Acad. Sci. USA 100 2003 10067-10072
28. P. Puigserver B.M. Spiegelman Peroxisome proliferators-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): Transcriptional coactivator and metabolic regulator Endocrinol. Rev. 24 2003 78-90
29. L. Abu-Elheiga et al. Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets Proc. Natl. Acad. Sci. USA 100 2003 10207-10212
30. J. Fruebis et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice Proc. Natl. Acad. Sci. USA 98 2001 2005-2010
31. S.J. Smith et al. Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking DGAT Nat. Genet. 25 2000 87-90
32. M. Elchebly et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene Science 283 1999 1544-1548